Cellectar Biosciences (NASDAQ: CLRB) shares Q2 2025 results update

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 and is incorporated by reference. The company’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol CLRB.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001279704 0001279704 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

Cellectar Biosciences, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware		1-36598		04-3321804
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 Campus Drive, Florham Park, NJ, 07932

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (608) 441-8120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		CLRB		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, we issued a press release announcing our financial results for the quarter ended June 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Number		Title
99.1		Press release dated August 14, 2025, titled “Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update”
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CELLECTAR BIOSCIENCES, INC.
Date: August 14, 2025	By:	/s/ Chad J. Kolean
	Name:	Chad J. Kolean
	Title:	Chief Financial Officer

FAQ

What did Cellectar Biosciences (CLRB) disclose in this 8-K?

The company disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update, which is furnished as Exhibit 99.1.

Which period’s results are covered in Cellectar Biosciences’ latest update?

The press release announced by Cellectar Biosciences covers financial results for the quarter ended June 30, 2025.

When was the Cellectar Biosciences Q2 2025 results press release issued?

The press release titled “Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update” was issued on August 14, 2025.

On which exchange is Cellectar Biosciences common stock listed and under what symbol?

Cellectar Biosciences’ common stock, par value $0.00001 per share, is listed on The Nasdaq Capital Market under the trading symbol CLRB.

Where can investors find the full Q2 2025 results and corporate update for Cellectar Biosciences?

Investors can find the full details in the press release furnished as Exhibit 99.1, titled “Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update.”

Who signed the Cellectar Biosciences current report related to the Q2 2025 results?

The report was signed on behalf of Cellectar Biosciences, Inc. by Chad J. Kolean, Chief Financial Officer.